title: [Evaluation of fourteen adult cases with visceral leishmaniasis].
abstract: Visceral leishmaniasis is a life threatening systemic infectious disease caused by Leishmania protozoon, which is transmitted by phlebotomine sandflies, and is widespread in Mediterranean countries including Turkey. The aim of this study was to retrospectively evaluate the visceral leishmaniasis cases followed in our clinic between January 2005 to April 2012, under the light of the current literature. A total of 14 cases (7 female, 7 male; age range: 19-64 years, mean age: 41.6 ± 12.9 years) diagnosed as visceral leishmaniasis and followed for one year after their treatment were included in the study. Data of the cases were obtained from the patient files. Ten of the cases were immunocompetent and four were immunosuppressive. While six of the cases were residents in Adana, eight were from different cities of south and southeastern Anatolia, Turkey. The median period between the development of symptoms and diagnosis was 75 (range: 2-272) days and 79% (11/14) of them were admitted to a health center and used antimicrobial agents. The leading presenting complaint was fever (100%) followed by chills and shiver (93%), weakness (71%) and weight loss (57%). Physical examination revealed fever in 8 (57%), splenomegaly in 11 (79%) and hepatosplenomegaly in 7 (50%) cases. Based on laboratory findings, pancytopenia was detected in 10 (71.4%) and hypoalbuminemia was detected in all (100%) of the cases. The diagnosis of visceral leishmaniasis was made by the detection of amastigote form of the parasite in the smears of bone marrow aspiration for 12 (86%) cases and of tissue (liver/spleen) biopsies for two cases. Bone marrow samples obtained from all of the patients were inoculated into NNN (Novy-MacNeal-Nicole) media and only 4 (29%) of them yielded the growth of Leishmania promastigots. Parenteral lipozomal amphotericin B was initiated to 10 immunocompetent patients at a dose of 3 mg/kg/day and to three immunosuppressive patients at a dose of 4 mg/kg/day. One immunosuppressive patient lost his life before initiation of treatment. With regard to disease progression, it was detected that two cases (of whom one was renal and one was bone marrow transplant patient) lost their lives (mortality rate: 14%), however all the other cases were cured completely. The present study comprised the highest number of visceral leishmaniasis adult cases reported in Turkey and enabled the review of disease characteristics. In conclusion, cases presenting with fever, hepatosplenomegaly, pancytopenia and hypoalbuminemia and living in endemic regions should be precisely evaluated in terms of visceral leishmaniasis.
authors: Baskent University Faculty of Medicine, Adana Practice and Research Center, Department of Infectious Diseases and Clinical Microbiology, Adana, Turkey. ebrukursun@hotmail.com.
authors: Ebru
authors: E
authors: Kurşun
authors: Tuba
authors: T
authors: Turunç
authors: Yusuf Ziya
authors: YZ
authors: Demiroğlu
authors: Soner
authors: S
authors: Solmaz
authors: Hande
authors: H
authors: Arslan
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage; D000981:Antiprotozoal Agents / Q000008:administration & dosage; D001853:Bone Marrow / Q000469:parasitology; D005260:Female; D006801:Humans; D007121:Immunocompetence; D016867:Immunocompromised Host; D007891:Leishmania / Q000302:isolation & purification; D007898:Leishmaniasis, Visceral / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology; D008081:Liposomes; D008099:Liver / Q000469:parasitology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013154:Spleen / Q000469:parasitology; D014421:Turkey / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000981:Antiprotozoal Agents; D008081:Liposomes; C068538:liposomal amphotericin B; D000666:Amphotericin B